Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+metastatic breast cancer

被引：1
|
作者：
Xu, B.
Ma, F.
Chen, S.
Li, Q.
Yang, F.
Zhang, Y.
Chen, X.
Zhong, D.
Zhang, G.
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[2] Chinese Acad Sci, Inst Mat Med, Shanghai, Peoples R China
[3] Jiangsu Hengrui Med Co LTD, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-18
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Ma, Fei
    Li, Qiao
    Chen, Shanshan
    Zhu, Wenjie
    Fan, Ying
    Wang, Jiayu
    Luo, Yang
    Xing, Puyuan
    Lan, Bo
    Li, Meiying
    Yi, Zongbi
    Cai, Ruigang
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) : 3105 - +
  • [2] NERATINIB (HKI-272), AN IRREVERSIBLE PAN ERBB RECEPTOR TYROSINE KINASE INHIBITOR: PHASE 2 RESULTS IN PATIENTS WITH ERBB2+ADVANCED BREAST CANCER
    Paridaens, R.
    Badwe, R.
    Sun, Y.
    Dirix, L.
    Cardoso, F.
    Powell, C.
    Zacharchuk, C.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2009, 20 : 61 - 61
  • [3] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [4] Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
    Ocana, Alberto
    Amir, Eitan
    CANCER TREATMENT REVIEWS, 2009, 35 (08) : 685 - 691
  • [5] A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
    Rixe, Olivier
    Franco, Sandra X.
    Yardley, Denise A.
    Johnston, Stephen R.
    Martin, Miguel
    Arun, Banu K.
    Letrent, Stephen P.
    Rugo, Hope S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1139 - 1148
  • [6] A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
    Olivier Rixe
    Sandra X. Franco
    Denise A. Yardley
    Stephen R. Johnston
    Miguel Martin
    Banu K. Arun
    Stephen P. Letrent
    Hope S. Rugo
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1139 - 1148
  • [7] A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
    Wong, Kwok-K.
    Fracasso, Paula M.
    Bukowski, Ronald M.
    Lynch, Thomas J.
    Munster, Pamela N.
    Shapiro, Geoffrey I.
    Jaenne, Pasi A.
    Eder, Joseph P.
    Naughton, Michael J.
    Ellis, Matthew J.
    Jones, Suzanne F.
    Mekhail, Tarek
    Zacharchuk, Charles
    Vermette, Jennifer
    Abbas, Richat
    Quinn, Susan
    Powell, Christine
    Burris, Howard A.
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2552 - 2558
  • [8] HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer.
    Burstein, H.
    Awada, A.
    Badwe, R.
    Dirix, L.
    Tan, A.
    Jacod, S.
    Lustgarten, S.
    Vermette, J.
    Zacharchuk, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S268 - S268
  • [9] Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
    Sequist, Lecia V.
    Besse, Benjamin
    Lynch, Thomas J.
    Miller, Vincent A.
    Wong, Kwok K.
    Gitlitz, Barbara
    Eaton, Keith
    Zacharchuk, Charles
    Freyman, Amy
    Powell, Christine
    Ananthakrishnan, Revathi
    Quinn, Susan
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 3076 - 3083
  • [10] Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+breast cancer
    Burstein, H. J.
    Sun, Y.
    Tan, A. R.
    Dirix, L.
    Vermette, J. J.
    Powell, C.
    Zacharchuk, C.
    Badwe, R. A.
    CANCER RESEARCH, 2009, 69 (02) : 72S - 73S
12345